Aeterna Zentaris (AEZS) 0.54 $AEZS Aeterna Zentaris

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aeterna Zentaris (AEZS) 0.54 $AEZS

Aeterna Zentaris prices public offering
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 5:54PM CST

AEZS: 0.54 (-0.25)

Aeterna Zentaris initiates capital raise
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 4:07PM CST

AEZS: 0.54 (-0.25)

Aeterna Zentaris to Present at Roth Conference 2015
CNW Group - Mon Mar 02, 1:35PM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced that the Company's Chairman and CEO, David Dodd, will be presenting a corporate overview and update at the 27(th) Annual Roth Conference on Wednesday, March 11, 2015, at 11:00 am (Pacific), in the Colonnade Room (Track 4) of the Ritz-Carlton Laguna Niguel Hotel, in Dana Point, California.
AEZ.TO: 0.66 (-0.34), AEZS: 0.54 (-0.25)

Stock to Watch: AEterna Zentaris Up 6.7% (AEZS)
Comtex SmarTrend(R) - Tue Feb 17, 10:36AM CST
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing penny stocks, up 6.7% to $0.57 on 1.3x average daily volume. AEterna Zentaris has traded 480,000 shares thus far today, vs. average volume of 362,000 shares per day. The stock has outperformed the Dow (6.7% to the Dow's -0.2%) and outperformed the S&P 500 (6.7% to the S&P's -0.1%) during today's trading.
AEZS: 0.54 (-0.25)

Recent Developments at Pharma Companies: Special Research on Aerie Pharmaceuticals, AEterna Zentaris, Affimed, Agenus, and Agile Therapeutics
PR Newswire - Tue Feb 03, 7:30AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Aerie Pharmaceuticals (NASDAQ: AERI), AEterna Zentaris (NASDAQ: AEZS), Affimed (NASDAQ: AFMD), Agenus (NASDAQ: AGEN), and Agile Therapeutics (NASDAQ: AGRX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AGEN: 5.11 (-0.17), AGRX: 10.65 (-0.34), AFMD: 5.89 (-0.12), AEZS: 0.54 (-0.25), AERI: 28.29 (-0.63)

Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST

BCRX: 10.05 (-0.18), ACT: 289.92 (-5.78), VRX: 198.71 (-5.24), PCYC: 254.56 (+0.34), ZSPH: 48.42 (-0.53), RMTI: 10.30 (-0.11), BCLI: 4.39 (+0.02), SIEN: 19.75 (+0.34), JNJ: 100.11 (-2.41), ECYT: 6.21 (-0.04), SNY: 47.42 (-0.94), LENS: 7.34 (-0.05), REGN: 422.13 (-6.82), SYK: 90.07 (-2.92), PFE: 33.97 (-0.50), SLXP: 158.01 (+0.57), AMGN: 154.88 (-4.72), APPY: 0.56 (-0.02), MNKD: 5.47 (-0.26), CELG: 118.03 (-2.68), ISRG: 494.04 (-5.48), GILD: 101.81 (-1.61), ANIP: 66.72 (+0.21), MRK: 56.84 (-1.14), ALXN: 181.65 (-4.14), CCXI: 7.74 (-0.24), ICPT: 266.14 (+4.96), AEZS: 0.54 (-0.25), ATRS: 2.69 (-0.07), NASH: 31.85 (-0.45)

Why I'm Upgrading AEterna Zentaris On Valuation
Daniel Ward - at Seeking Alpha - Tue Jan 27, 10:07AM CST

AEZS: 0.54 (-0.25)

UPDATE - MONDAY DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors Of Class Action Against Aeterna Zentaris Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of January 12, 2015 -- AEZS
PR Newswire - Fri Jan 09, 12:31PM CST
Levi & Korsinsky announces that the class period for a case commenced on behalf of Aeterna Zentaris Inc. ("Aeterna Zentaris" or the "Company" (Nasdaq: AEZS) shareholders has expanded to include shareholders who purchased shares between April 2, 2012 and November 6, 2014.
AEZS: 0.54 (-0.25)

Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against Aeterna Zentaris Inc. and Lead Plaintiff Deadline of January 12, 2015
PR Newswire - Thu Jan 08, 9:00AM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court for the Southern District of New York on behalf of those who purchased shares of Aeterna Zetaris Inc. ("Aeterna Zentaris" or the "Company" (NasdaqCM:AEZS) shares during the period between April 2, 2012 and November 6, 2014 (the "Class Period" .
AEZS: 0.54 (-0.25)

INVESTOR ALERT: Glancy Binkow & Goldberg LLP Announces an Expanded Class Period in the Shareholder Lawsuit Against Aeterna Zentaris Inc.
Business Wire - Tue Jan 06, 6:18PM CST
Glancy Binkow & Goldberg LLP announces that a class action complaint has been filed with an expanded Class Period in the shareholder lawsuit pending in the United States District Court for the District of New Jersey against Aeterna Zentaris Inc. ("Aeterna" or the "Company" (NASDAQ:AEZS). The complaint alleges violations of federal securities laws and asserts claims on behalf of purchasers of Aeterna securities between April 2, 2012 and November 6, 2014, inclusive (the "Class Period" .
AEZS: 0.54 (-0.25)

EQUITY UPDATE: Rosen Law Firm Expands Class Period in Aeterna Zentaris, Inc. Investor Class Action to Include Purchasers Between April 2, 2012 and November 6, 2014 - AEZS
Business Wire - Tue Jan 06, 3:47PM CST
Rosen Law Firm has filed a complaint expanding the class action to now include purchasers of Aeterna Zentaris, Inc. securities (NASDAQ:AEZS) between April 2, 2012 and November 6, 2014. The Firm also reminds investors of the important January 12, 2015 lead plaintiff deadline.
AEZS: 0.54 (-0.25)

INVESTOR ALERT: Investors of Aeterna Zentaris Inc. With Losses of $100,000 or More Are Encouraged to Contact Law Offices of Howard G. Smith
Business Wire - Tue Jan 06, 2:38PM CST
Law Offices of Howard G. Smith reminds investors that purchasers of the securities of Aeterna Zentaris Inc. ("Aeterna" or the "Company" (NASDAQ:AEZS) between October 18, 2012 and November 5, 2014, inclusive (the "Class Period" , have until January 12, 2015, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit. Investors who have losses of $100,000 or more are encouraged to contact the firm for more information.
AEZS: 0.54 (-0.25)

Aeterna Zentaris to Present at Upcoming Biotech Showcase Conference in San Francisco
PR Newswire - Tue Jan 06, 6:30AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced that the Company's Chairman and CEO, David Dodd, will be presenting a corporate overview at the 7th annual Biotech Showcase Conference on Wednesday, January 14, 2015, at 3:30 pm (Pacific), in the C-Mission II room (4th floor) of the Parc 55 Wyndham San Francisco - Union Square Hotel.
AEZ.TO: 0.66 (-0.34), AEZS: 0.54 (-0.25)

SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Aeterna Zentaris Inc. and Its Board of Directors and a Lead Plaintiff Deadline of January 12, 2015
Business Wire - Mon Jan 05, 12:18PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Aeterna Zentaris Inc. ("Aeterna Zentaris" or the "Company" (Nasdaq: AEZS) securities between October 18, 2012 and November 5, 2014.
AEZS: 0.54 (-0.25)

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Aeterna Zentaris, Inc. of Class Action Lawsuit and Upcoming Deadline -- AEZS
GlobeNewswire - Sat Jan 03, 6:00PM CST
Pomerantz LLP has filed a class action lawsuit against Aeterna Zentaris, Inc. ("Aeterna" or the "Company" (Nasdaq:AEZS) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons or entities who purchased Aeterna securities between June 26, 2012 and November 5, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
AEZS: 0.54 (-0.25)

Benign Prostatic Hyperplasia - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/nqt9vr/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AEterna Zentaris - Addex Therapeutics - AmVac - Aphios Corporation - Astellas Pharma Inc. - Ausio Pharmaceuticals - Biolab Sanus Farmaceutica - Chong Kun Dang Pharmaceutical - Chugai Pharmaceutical - Curadis GmbH - Euroscreen S.A. - Hanmi Pharmaceuticals - IntelGenx - KAEL-GemVax - Kaken Pharmaceutical - Mezzion Pharma - Nymox Pharmaceutical - Ono Pharmaceutical - Quest PharmaTech - SK Chemicals - SOM Biotech - Sophiris Bio - Yungjin Pharm For more information visit http://www.researchandmarkets.com/research/nq..._prostatic
SPHS: 0.70 (-0.03), AEZS: 0.54 (-0.25), NYMX: 0.58 (-0.03)

SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Aeterna Zentaris Inc. and Its Board of Directors and a Lead Plaintiff Deadline of January 12, 2015 -- AEZS
GlobeNewswire - Mon Dec 29, 3:02PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Aeterna Zentaris Inc. ("Aeterna Zentaris" or the "Company" (Nasdaq:AEZS) securities between October 18, 2012 and November 5, 2014.
AEZS: 0.54 (-0.25)

Aeterna Zentaris: Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin in Prostate Cancer Published in Clinical Cancer Research
PR Newswire - Mon Dec 29, 6:30AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company" today announced that an article on final data for the Phase 1 portion of the ongoing Phase 1/2 trial in prostate cancer with zoptarelin doxorubicin (formerly AEZS-108), a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, has been published in the December issue of Clinical Cancer Research. The article outlines data previously disclosed in June 2013 at the American Society of Clinical Oncology's ("ASCO" Annual Meeting, which demonstrated the compound's safety profile and promising anti-tumor activity in heavily pre--treated men with castration- and taxane-resistant prostate cancer. These results led to the current investigator-driven Phase 2 portion in this same indication under the supervision of lead investigator, Jacek Pinski, MD, PhD, of the USC Norris Comprehensive Cancer Center. Titled, "Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer", Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, Tai YC, Engel J, Hawes D, Schally AV, Pinski J., the article is available at this link: Clin Cancer Res.
AEZ.TO: 0.66 (-0.34), AEZS: 0.54 (-0.25)

SECURITIES ALERT: Rosen Law Firm Reminds Aeterna Zentaris, Inc. Investors of Important January 12, 2015 Deadline in Class Action Filed by the Firm -- AEZS
GlobeNewswire - Sat Dec 27, 11:01PM CST
Rosen Law Firm reminds purchasers of Aeterna Zentaris, Inc. securities (Nasdaq:AEZS) between October 18, 2012 and November 6, 2014 of the important January 12, 2015 lead plaintiff deadline in the class action filed by the firm.
AEZS: 0.54 (-0.25)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Endava's Audit Scandal: Investors Face Crucial Decision

Updated Category News Views 14

Endava's Unexpected Crisis: What's Happening? It's the kind of mess no investor wants to wake up to: on October 28, 2026, Endava plc (NYSE: DAVA) laid out a smorgasbord of screw-ups that have left the market reeling. The company's last few days were a whirlwind, featuring the CFO's abrupt exit and the CEO swap. This shake-up didn't happen in isolation—the announcement...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 25

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 193

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Salvation Army’s Angel Tree: 2026 Holiday Cheer Drive

Updated Category News Views 9

Kickstarting Holiday Generosity: The Angel Tree Program Man, there's something heartwarming about a Christmas that shines bright for everyone. The Salvation Army's Angel Tree program is back for another season, rolling up with a mission to spark joy across the country. For over 45 years now, this initiative's been the answer to many Christmas wish lists, especially for...

Continue Reading
Veritran's Bold Move: Acquiring PrismaCampaigns Inc.

Updated Category News Views 58

Veritran's Strategic Leap Forward They're not messing around, folks. Veritran just made a power move by acquiring 100% of PrismaCampaigns Inc., and it’s more than just another day in the office. This marks a pivotal expansion of their American footprint, and they're zeroing in on our banks and credit unions with laser precision. Why This Matters for Financial...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 74

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 117

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Cinmoore's Smart Camera: A Game Changer for Car Security

Updated Category News Views 32

Pioneering Car Security with Cinmoore's Smart Camera Ever left your car in the parking lot, heart pounding, wondering if it's safe while you run errands? Well, Cinmoore might just quell that parking paranoia with their new gizmo, the Smart Parking Camera DC1U. This device isn't just some fancily-packaged disappointment—it promises some serious peace of mind for those...

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 80

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading
Baidu's Q3 2026: AI Explodes Amid Marketing Slump

Updated Category News Views 35

Baidu Looks to AI as Revenue Driver in Q3 2026 You know, Baidu's got one heck of a story this quarter. Despite some clouds hanging over them, they’ve managed to find a silver lining in their AI ventures. It’s like they’ve got this magic bullet with AI Cloud growth skyrocketing 94% year over year. That’s not just a rabbit outta the hat; it’s more like pulling a...

Continue Reading

Top 5 Most Recently Viewed Articles

AEX Index Climbs as Technology Sector Shines Bright

Updated Category News Views 246

AEX Index Climbs as Technology Sector Shines Bright The AEX index in the Netherlands showcased a remarkable performance following gains across multiple sectors during a recent trading session. The technology, consumer goods, and consumer services sectors were significant contributors to this upward trend, reflecting the overall market optimism. Market Performance Overview...

Continue Reading
Comoto Partners with Motorcycle Industry Council to Boost Riding

Updated Category News Views 337

Comoto and the MIC Collaborate for Motorcycling Growth The Comoto Family of Brands, which includes names like Cycle Gear, RevZilla, and J&P Cycles, has recently announced an exciting partnership with the Motorcycle Industry Council (MIC). This collaboration aims to ignite the passion for motorcycle riding among new and potential riders through innovative educational...

Continue Reading
Oxford Treatment Center Launches Evening Addiction Services

Updated Category News Views 288

Oxford Treatment Center Enhances Addiction Care Availability Oxford Treatment Center is excited to announce the launch of its new evening intensive outpatient program (IOP), designed specifically for those in Southaven seeking flexible addiction care. This initiative addresses a crucial gap in services for individuals juggling daytime obligations, such as work or school,...

Continue Reading
Anticipating Earnings: Insights for MeridianLink (MLNK)

Updated Category News Views 146

MeridianLink's Earnings Outlook MeridianLink (NYSE: MLNK) is gearing up to announce its quarterly earnings soon, which has investors excited about what lies ahead. As the moment approaches, there are critical factors that stakeholders should consider to navigate the upcoming report effectively. Anticipated Earnings Analysis Expectations are set for MeridianLink to unveil...

Continue Reading
BCT - The Community's Bank Celebrates Loudoun's Favorite Honors

Updated Category News Views 145

BCT - The Community's Bank Wins Loudoun's Favorite Awards BCT - The Community's Bank has been recognized by residents as one of Loudoun's Favorite banks, having won multiple awards in the recent annual reader's poll. This recognition reflects the bank's unwavering dedication to providing top-notch financial services to its local community. For the second consecutive year,...

Continue Reading